ĐÁNH GIÁ HỆ THỐNG TUẦN HOÀN BÀNG HỆ NGOÀI GAN TRONG ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN BẰNG NÚT HÓA CHẤT ĐỘNG MẠCH QUA CATHETER

Abstract

SUMMARY

Hepatocellular carcinoma (HCC) is a leading cause of morbidity
and mortality, ranking fi fth for men and eighth for women as a source of primary malignancy. The highest incidences of HCC are found in sub-Saharan Africa and Eastern Asia, Southeastern Asia with incidence rates of 17.43 and 6.77 per 100,000 in men and women of developing countries compared with 8.71 and 2.86 per 100,000 in men and women of developed regions of the world [2],[6]. The three curative options of resection, liver transplantation, and percutaneous ablation compete as fi rst-line treatment modalities for early HCC, achieving 5-year survival rates of 50-70% [18]. At these advanced stages of HCC, arterial embolization techniques combined with intra-arterial chemotherapy has been shown to be an effective palliative therapy that can also improve patient survival [19],[20]. HCC chemoembolization is based on the fact that the normal liver parenchyma receives a dual blood supply from the hepatic artery and the portal vein, whereas HCCs are supplied exclusively by the hepatic artery. In practice, many HCCs are supplied by extrahepatic collateral arteries even when the hepatic artery is patent [13],[19]. Detect these extraheparic colateral vessel supply as well as ways in which to improve the effective and avoid complications of TACE of the collateral vessels.